JP2014505108A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014505108A5 JP2014505108A5 JP2013553575A JP2013553575A JP2014505108A5 JP 2014505108 A5 JP2014505108 A5 JP 2014505108A5 JP 2013553575 A JP2013553575 A JP 2013553575A JP 2013553575 A JP2013553575 A JP 2013553575A JP 2014505108 A5 JP2014505108 A5 JP 2014505108A5
- Authority
- JP
- Japan
- Prior art keywords
- less
- pharmaceutically acceptable
- acceptable salt
- hydrate
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000003839 salts Chemical class 0.000 claims description 163
- 239000012453 solvate Substances 0.000 claims description 142
- 101710084141 Synaptic vesicle glycoprotein 2A Proteins 0.000 claims description 73
- 239000003112 inhibitor Substances 0.000 claims description 70
- 208000010877 cognitive disease Diseases 0.000 claims description 60
- 239000000203 mixture Substances 0.000 claims description 50
- 229960004002 levetiracetam Drugs 0.000 claims description 33
- HPHUVLMMVZITSG-ZCFIWIBFSA-N levetiracetam Chemical compound CC[C@H](C(N)=O)N1CCCC1=O HPHUVLMMVZITSG-ZCFIWIBFSA-N 0.000 claims description 33
- 210000003169 central nervous system Anatomy 0.000 claims description 30
- 208000028698 Cognitive impairment Diseases 0.000 claims description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 229960002161 brivaracetam Drugs 0.000 claims description 27
- MSYKRHVOOPPJKU-BDAKNGLRSA-N brivaracetam Chemical compound CCC[C@H]1CN([C@@H](CC)C(N)=O)C(=O)C1 MSYKRHVOOPPJKU-BDAKNGLRSA-N 0.000 claims description 27
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 claims description 27
- 229940102566 valproate Drugs 0.000 claims description 27
- ANWPENAPCIFDSZ-BQBZGAKWSA-N seletracetam Chemical compound CC[C@@H](C(N)=O)N1C[C@@H](C=C(F)F)CC1=O ANWPENAPCIFDSZ-BQBZGAKWSA-N 0.000 claims description 19
- 229950000852 seletracetam Drugs 0.000 claims description 19
- 230000006999 cognitive decline Effects 0.000 claims description 15
- 208000015114 central nervous system disease Diseases 0.000 claims description 7
- 239000008280 blood Substances 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 5
- 206010012289 Dementia Diseases 0.000 claims description 4
- 208000027061 mild cognitive impairment Diseases 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 22
- 230000003920 cognitive function Effects 0.000 claims 11
- 150000004677 hydrates Chemical class 0.000 claims 9
- 238000013265 extended release Methods 0.000 claims 5
- 238000004519 manufacturing process Methods 0.000 claims 5
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 230000001149 cognitive effect Effects 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 1
- 238000011260 co-administration Methods 0.000 claims 1
- 230000007423 decrease Effects 0.000 claims 1
- 230000001934 delay Effects 0.000 claims 1
- 230000003111 delayed effect Effects 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
- 230000000946 synaptic effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 95
- 239000008194 pharmaceutical composition Substances 0.000 description 11
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161441251P | 2011-02-09 | 2011-02-09 | |
| US61/441,251 | 2011-02-09 | ||
| PCT/US2012/024556 WO2012109491A1 (en) | 2011-02-09 | 2012-02-09 | Methods and compositions for improving cognitive function |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132218A Division JP2016172772A (ja) | 2011-02-09 | 2016-07-04 | 認知機能を改善するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014505108A JP2014505108A (ja) | 2014-02-27 |
| JP2014505108A5 true JP2014505108A5 (enExample) | 2015-04-02 |
Family
ID=46638963
Family Applications (7)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013553575A Withdrawn JP2014505108A (ja) | 2011-02-09 | 2012-02-09 | 認知機能を改善するための方法および組成物 |
| JP2016132218A Withdrawn JP2016172772A (ja) | 2011-02-09 | 2016-07-04 | 認知機能を改善するための方法および組成物 |
| JP2018060195A Withdrawn JP2018100305A (ja) | 2011-02-09 | 2018-03-27 | 認知機能を改善するための方法および組成物 |
| JP2020033698A Pending JP2020079318A (ja) | 2011-02-09 | 2020-02-28 | 認知機能を改善するための方法および組成物 |
| JP2021131734A Pending JP2021175759A (ja) | 2011-02-09 | 2021-08-12 | 認知機能を改善するための方法および組成物 |
| JP2023119159A Withdrawn JP2023126654A (ja) | 2011-02-09 | 2023-07-21 | 認知機能を改善するための方法および組成物 |
| JP2025077648A Pending JP2025109773A (ja) | 2011-02-09 | 2025-05-07 | 認知機能を改善するための方法および組成物 |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016132218A Withdrawn JP2016172772A (ja) | 2011-02-09 | 2016-07-04 | 認知機能を改善するための方法および組成物 |
| JP2018060195A Withdrawn JP2018100305A (ja) | 2011-02-09 | 2018-03-27 | 認知機能を改善するための方法および組成物 |
| JP2020033698A Pending JP2020079318A (ja) | 2011-02-09 | 2020-02-28 | 認知機能を改善するための方法および組成物 |
| JP2021131734A Pending JP2021175759A (ja) | 2011-02-09 | 2021-08-12 | 認知機能を改善するための方法および組成物 |
| JP2023119159A Withdrawn JP2023126654A (ja) | 2011-02-09 | 2023-07-21 | 認知機能を改善するための方法および組成物 |
| JP2025077648A Pending JP2025109773A (ja) | 2011-02-09 | 2025-05-07 | 認知機能を改善するための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20120214859A1 (enExample) |
| EP (2) | EP2672822A4 (enExample) |
| JP (7) | JP2014505108A (enExample) |
| CN (2) | CN109662961A (enExample) |
| AU (6) | AU2012214303A1 (enExample) |
| BR (1) | BR112013020283A2 (enExample) |
| CA (1) | CA2826765C (enExample) |
| RU (1) | RU2665021C2 (enExample) |
| WO (1) | WO2012109491A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018208662B2 (en) * | 2012-11-14 | 2020-07-23 | The Johns Hopkins University | Methods and Compositions for Treating Schizophrenia |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| EP2968257A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| CN105142623A (zh) | 2013-03-15 | 2015-12-09 | 艾吉因生物股份有限公司 | 用于改善认知功能的方法和组合物 |
| EP2968237A4 (en) | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
| PT3096790T (pt) | 2014-01-21 | 2019-10-15 | Janssen Pharmaceutica Nv | Combinações compreendendo moduladores alostéricos positivos ou agonistas ortostéricos do recetor glutamatérgico metabotrópico do subtipo 2 e seu uso |
| EA202192105A3 (ru) | 2014-02-04 | 2022-02-28 | Янссен Фармацевтика Нв | Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение |
| CN107810002B (zh) * | 2015-05-22 | 2021-01-05 | 艾吉因生物股份有限公司 | 左乙拉西坦的延时释放药物组合物 |
| WO2021063414A1 (zh) * | 2019-09-30 | 2021-04-08 | 厦门大学 | 戊酸衍生物在治疗唐氏综合征中的应用 |
| EP4499154A1 (en) | 2022-03-25 | 2025-02-05 | REGENXBIO Inc. | Dominant-negative tumor necrosis factor alpha adeno-associated virus gene therapy |
| EP4572852A1 (en) | 2022-08-19 | 2025-06-25 | Agenebio, Inc. | Benzazepine derivatives, compositions, and methods for treating cognitive impairment |
| CN115517682B (zh) * | 2022-11-25 | 2023-01-31 | 四川大学华西医院 | 基于胃肠电信号的认知功能障碍预测系统及构建方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9319732D0 (en) * | 1993-09-24 | 1993-11-10 | Ucb Sa | Use of (s)-alpha-ethyl-2-oxo-l-pyrrolidineacetamide for the treatment of anxiety |
| GB0004297D0 (en) * | 2000-02-23 | 2000-04-12 | Ucb Sa | 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses |
| US7090985B2 (en) * | 2002-12-03 | 2006-08-15 | Ucb, S.A. | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| US20070135514A1 (en) * | 2002-12-03 | 2007-06-14 | Berkley Lynch | Methods for the identification of agents for the treatment of seizures, neurological diseases, endocrinopathies and hormonal diseases |
| CN101027047A (zh) * | 2002-12-03 | 2007-08-29 | Ucb公司 | 鉴定用于治疗癫痫发作、神经疾病、内分泌病和激素疾病的药剂的方法 |
| DK1626721T3 (en) * | 2003-05-23 | 2017-01-23 | Otsuka Pharma Co Ltd | CARBOSTYRIL DERIVATIVES AND Mood Stabilizers for the Treatment of Mood Disorders |
| US20070298098A1 (en) * | 2005-02-16 | 2007-12-27 | Elan Pharma International Limited | Controlled Release Compositions Comprising Levetiracetam |
| AU2006244297A1 (en) * | 2005-04-06 | 2006-11-16 | Adamas Pharmaceuticals, Inc. | Methods and compositions for treatment of CNS disorders |
| US20060241144A1 (en) * | 2005-04-20 | 2006-10-26 | Albert Cha | Method for treating apathy syndrome |
| PL1909764T3 (pl) * | 2005-07-26 | 2015-03-31 | Ucb Pharma Sa | Kompozycje farmaceutyczne zawierające lewetyracetam i sposób ich wytwarzania |
| AU2007223036A1 (en) * | 2006-03-08 | 2007-09-13 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| ES2444009T3 (es) * | 2006-06-08 | 2014-02-21 | Ucb Pharma, S.A. | Co-cristales de pirrolidinonas |
| WO2008062446A2 (en) * | 2006-09-14 | 2008-05-29 | Alembic Limited | An extended release composition of levetiracetam, which exhibits no adverse food effect |
| US20090176740A1 (en) * | 2007-11-30 | 2009-07-09 | Phillips Ii Dauglas James | Treatment of neurological conditions by the co-administration of aniracetam and l-alpha glycerylphosphorylcholine |
| JP2011529923A (ja) * | 2008-08-06 | 2011-12-15 | ゴスフォース センター（ホールディングス）プロプライエタリー リミテッド | 精神障害（ｐｓｙｃｈｉａｔｒｉｃｄｉｓｏｒｄｅｒ）を治療するための組成物および方法 |
| BRPI0920342A2 (pt) * | 2008-10-16 | 2020-06-23 | The Johns Hopkins University | Uso de um inibidor da proteína vesicular sináptica 2a (sv2a) ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica para melhora da função cognitiva, uso de levitiracetam ou um sal farmaceuticamente aceitável do mesmo, uso de brivaracetam ou um sal farmaceuticamente aceitável do mesmo, uso do seletracetam ou um sal farmaceuticamente aceitável do mesmo |
| US20100172979A1 (en) * | 2008-12-24 | 2010-07-08 | Zhongshui Yu | Controlled-release formulations |
| CN101647789B (zh) * | 2009-09-01 | 2011-08-17 | 天津药物研究院药业有限责任公司 | 左乙拉西坦缓释微丸胶囊制剂 |
| EP2533645B1 (en) * | 2010-02-09 | 2016-07-27 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2968237A4 (en) * | 2013-03-15 | 2016-08-31 | Univ Johns Hopkins | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION |
-
2012
- 2012-02-09 EP EP12744250.7A patent/EP2672822A4/en not_active Withdrawn
- 2012-02-09 CN CN201811403097.5A patent/CN109662961A/zh active Pending
- 2012-02-09 AU AU2012214303A patent/AU2012214303A1/en not_active Abandoned
- 2012-02-09 US US13/370,253 patent/US20120214859A1/en not_active Abandoned
- 2012-02-09 JP JP2013553575A patent/JP2014505108A/ja not_active Withdrawn
- 2012-02-09 EP EP18161109.6A patent/EP3400934A1/en not_active Ceased
- 2012-02-09 WO PCT/US2012/024556 patent/WO2012109491A1/en not_active Ceased
- 2012-02-09 CA CA2826765A patent/CA2826765C/en active Active
- 2012-02-09 BR BR112013020283A patent/BR112013020283A2/pt not_active Application Discontinuation
- 2012-02-09 CN CN201280014797XA patent/CN103476255A/zh active Pending
- 2012-02-09 RU RU2013141155A patent/RU2665021C2/ru active
-
2016
- 2016-04-27 AU AU2016202670A patent/AU2016202670A1/en not_active Abandoned
- 2016-07-04 JP JP2016132218A patent/JP2016172772A/ja not_active Withdrawn
-
2018
- 2018-02-22 AU AU2018201303A patent/AU2018201303A1/en not_active Abandoned
- 2018-03-27 JP JP2018060195A patent/JP2018100305A/ja not_active Withdrawn
-
2019
- 2019-11-19 AU AU2019268069A patent/AU2019268069A1/en not_active Ceased
-
2020
- 2020-02-28 JP JP2020033698A patent/JP2020079318A/ja active Pending
-
2021
- 2021-01-19 AU AU2021200325A patent/AU2021200325B2/en active Active
- 2021-08-12 JP JP2021131734A patent/JP2021175759A/ja active Pending
-
2022
- 2022-03-14 US US17/693,901 patent/US20230033195A1/en active Pending
- 2022-08-25 AU AU2022221492A patent/AU2022221492A1/en not_active Abandoned
-
2023
- 2023-07-21 JP JP2023119159A patent/JP2023126654A/ja not_active Withdrawn
-
2025
- 2025-05-07 JP JP2025077648A patent/JP2025109773A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014505108A5 (enExample) | ||
| KR102011641B1 (ko) | 치환된 퀴나졸리논을 위한 경구 즉시 방출 제형 | |
| JP2015512406A5 (enExample) | ||
| JP2013518914A5 (enExample) | ||
| CA2883751A1 (en) | Methods of treating alzheimer's disease and pharmaceutical compositions thereof | |
| JP2015528471A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2016517851A5 (enExample) | ||
| WO2012125475A1 (en) | Use of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl)piperidine-2-6-dione in treatment of immune-related and inflammatory diseases | |
| JP2012505883A5 (enExample) | ||
| UA102517C2 (ru) | Замещенные производные морфолина и тиоморфолина, фармацевтическая композиция на их основе и их применение для производства лекарственного средства для лечения расстройства или заболевания центральной нервной системы | |
| CA2893468C (en) | Use of vortioxetine and donepezil in the treatment of cognitive impairment | |
| RU2013141155A (ru) | Способы и композиции для улучшения когнитивных функций | |
| WO2011028794A2 (en) | Treatment of huntington's disease with cycloserine and an nmda receptor antagonist | |
| JP2016510343A5 (enExample) | ||
| JP2016514688A5 (enExample) | ||
| BR112023025552A2 (pt) | Composições estabilizadas de apilimod e usos das mesmas | |
| JP2015522077A5 (enExample) | ||
| JP2019518030A5 (enExample) | ||
| JP2014534229A5 (enExample) | ||
| CA2476939A1 (en) | Pharmaceutical combinations of cox-2 inhibitors and opiates | |
| JP2008540405A5 (enExample) | ||
| JP2018531961A5 (enExample) | ||
| RU2007132971A (ru) | Способы и материалы с транс-кломифеном для лечения мужского бесплодия | |
| US5441963A (en) | Potentiation of NMDA antagonists |